DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD.

Andere talen Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Aandelen

688192

CNE1000055W8

slotkoers Shanghai S.E. Andere beurzen 00:00:00 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
44,39 ^CNY	+3,26%		+25,40%	-7,23%

24/04	Dizal (Jiangsu) Pharmaceutical Co, Ltd. Twee samenvattingen met de nieuwste gegevens over sunvozertinib in niet-kleincellige longkanker	CI
07/04	U.S. Food and Drug Administration kent doorbraaktherapie-aanduiding toe aan sunvozertinib van Dizal voor de eerstelijns behandeling van patiënten met gevorderde niet-kleincellige longkanker met EGFR-exon 20-invoegingsmutaties	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Dizal Pharmaceutical Co., Ltd. Announces Two Abstracts Featuring the Latest Data on Sunvozertinib in Non-Small Cell Lung Cancer	24/04
U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Dizal's Sunvozertinib for the First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations	07/04
Dizal Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	23/02
Dizal's Sunvozertinib Pivotal Study Results Published in The Lancet Respiratory Medicine	13/12
Dizal Pharmaceutical Co., Ltd.(SHSE:688192) added to Shanghai Stock Exchange Health Care Sector Index	11/12
Dizal's Golidocitinib Pivotal Trial Demonstrates Superior and Durable Clinical Benefits for Patients with r/r PTCL in Oral Presentation at 2023 ASH	10/12
Dizal Pharma to Invest 700 Million Yuan in New Dermatology Venture	22/11
Dizal Pharma Presents Positive Results of Lung Cancer Drug	24-10-23
Dizal Announces Latest Research Findings on the Efficacy and Safety of Sunvozertinib in Treatment-Naive Patients	23-10-23
Chinese Drug Regulator Puts Dizal Pharma's Lymphoma Drug in Priority Review	22-09-23
Dizal Pharmaceutical Receives Priority Review by China NMPA for the Treatment of r/r PTCL	21-09-23
Dizal Pharmaceutical Co., Ltd.(XSSC:688192) added to S&P Global BMI Index	18-09-23
Dizal Pharmaceutical Co., Ltd. Announces China CDE Acceptance of New Drug Application for Golidocitinib for Relapsed or Refractory PTCL	14-09-23
Dizal (Jiangsu) Pharmaceutical's Anti-Lymphoma Medication Research Results Published in European Oncology Journal	11-09-23
Dizal Pharmaceutical Announces Clinical Results of Golidocitinib Published in Annals of Oncology	10-09-23
Anova Enterprises, Inc. Partners with Dizal Pharmaceuticals to Accelerate Development of DZD9008 for Patients with Advanced or Metastatic NSCLC with EGFR Exon20 Insertion Mutation	06-09-23
Dizal Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	29-08-23
Dizal's Sunvozertinib Approves by China NMPA with Potential for Best-In-Class Therapy in NSCLC with EGFR Exon20ins Mutations	23-08-23
Dizal Will Present the Results of Molecular Analysis on EGFR Exon20ins Mutations in Tumor Tissue and Plasma ctDNA	17-08-23
Dizal Pharma Gets European Regulator's Nod to Hold Tumor Drug Trial	13-06-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Aandelen

688192

CNE1000055W8

Andere talen

Filters